Repeated immunizations with whole Plasmodium blood stage parasites and concomitant
drug cure of
infection confer protective immunity against parasite challenge in mice, monkeys and humans. Moreover, it was recently shown that
infections with genetically modified rodent
malaria blood stage parasites conferred sterile protection against lethal blood stage challenge. However, in these models vaccination resulted in high
parasitemias and, in consequence, carries risk of
vaccine-induced pathology and death. Herein, we generated a novel, completely blood stage-attenuated P. yoelii rodent
malaria strain by targeted deletion of parasite
nucleoside transporter 1 (NT1). Immunization of inbred and outbred mouse strains with a single low dose of Pynt1(-) blood stages did not induce any patent
infections and conferred complete sterile protection against lethal heterologous blood stage and sporozoite challenges. Partial protection was observed against lethal challenges with another parasite species, P. berghei. Importantly, subcutaneous immunization with Pynt1(-) conferred sterile protection against lethal blood stage challenges. We show that cellular and humoral immune responses are both essential for sterile protection. The study demonstrates that genetic manipulation provides a platform for the designed, complete attenuation of
malaria parasite blood stages and suggests testing the safety and efficacy of P. falciparum NT1 knockout strains in humans.